UroGen Pharma (URGN) Interest Coverage Ratio (2017 - 2026)
UroGen Pharma's (URGN) quarterly Interest Coverage Ratio came in at 3.68 in Q1 2026, up 97.8% YoY from 1.86 in Q1 2025, and up 95.3% on a QoQ basis from 78.34 in Q4 2025.
UroGen Pharma (URGN) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Interest Coverage Ratio data on file, last reported at 3.68 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 97.8% year-over-year to 3.68 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19.67 (up 81.65% YoY) and the FY2025 annual result came in at 0.63, down 9.58% from the prior year.
- Interest Coverage Ratio grew to 3.68 in Q1 2026, from 78.34 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 3.68 in Q1 2026 to a low of 167.79 in Q1 2025.
- A 5-year average of 43.83 and a median of 15.99 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio surged 99.91% — and 2024, when it plunged 1027.99%.
- Tracing URGN's Interest Coverage Ratio over 5 years: stood at 68.99 in 2022, then increased by 27.23% to 50.2 in 2023, then tumbled by 151.56% to 126.29 in 2024, then jumped by 37.97% to 78.34 in 2025, then soared by 95.3% to 3.68 in 2026.
- The last three Interest Coverage Ratio figures came in at 3.68 (Q1 2026), 78.34 (Q4 2025), and 4.56 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 0.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.02 |
| Mar 31, 2026 | -3.68 |
| Dec 31, 2025 | -78.34 |
| Sep 30, 2025 | -4.56 |
| Jun 30, 2025 | -8.64 |
| Mar 31, 2025 | -167.79 |
| Dec 31, 2024 | -126.29 |
| Sep 30, 2024 | -15.99 |
| Jun 30, 2024 | -19.74 |
| Mar 31, 2024 | -92.92 |
| Dec 31, 2023 | -50.20 |
| Sep 30, 2023 | -6.48 |
| Jun 30, 2023 | -6.50 |
| Mar 31, 2023 | -8.24 |
| Dec 31, 2022 | -68.99 |
| Sep 30, 2022 | -5.60 |
| Jun 30, 2022 | -6.98 |
| Mar 31, 2022 | -74.18 |
| Dec 31, 2021 | 13.89 |
| Jun 30, 2021 | -7,607.67 |